Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19

整合血浆蛋白质组学和单细胞免疫信号网络特征可区分轻症、中症和重症 COVID-19

阅读:6
作者:Dorien Feyaerts ,Julien Hédou ,Joshua Gillard ,Han Chen ,Eileen S Tsai ,Laura S Peterson ,Kazuo Ando ,Monali Manohar ,Evan Do ,Gopal K R Dhondalay ,Jessica Fitzpatrick ,Maja Artandi ,Iris Chang ,Theo T Snow ,R Sharon Chinthrajah ,Christopher M Warren ,Richard Wittman ,Justin G Meyerowitz ,Edward A Ganio ,Ina A Stelzer ,Xiaoyuan Han ,Franck Verdonk ,Dyani K Gaudillière ,Nilanjan Mukherjee ,Amy S Tsai ,Kristen K Rumer ,Danielle R Jacobsen ,Zachary B Bjornson-Hooper ,Sizun Jiang ,Sergio Fragoso Saavedra ,Sergio Iván Valdés Ferrer ,J Daniel Kelly ,David Furman ,Nima Aghaeepour ,Martin S Angst ,Scott D Boyd ,Benjamin A Pinsky ,Garry P Nolan ,Kari C Nadeau ,Brice Gaudillière ,David R McIlwain

Abstract

The biological determinants underlying the range of coronavirus 2019 (COVID-19) clinical manifestations are not fully understood. Here, over 1,400 plasma proteins and 2,600 single-cell immune features comprising cell phenotype, endogenous signaling activity, and signaling responses to inflammatory ligands are cross-sectionally assessed in peripheral blood from 97 patients with mild, moderate, and severe COVID-19 and 40 uninfected patients. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identify and independently validate a multi-variate model classifying COVID-19 severity (multi-class area under the curve [AUC]training = 0.799, p = 4.2e-6; multi-class AUCvalidation = 0.773, p = 7.7e-6). Examination of informative model features reveals biological signatures of COVID-19 severity, including the dysregulation of JAK/STAT, MAPK/mTOR, and nuclear factor κB (NF-κB) immune signaling networks in addition to recapitulating known hallmarks of COVID-19. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for prevention and/or treatment of COVID-19 progression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。